Back to Journals » OncoTargets and Therapy » Volume 7

CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration

Authors Xi Y, Chen M, Liu X, Lu Z, Ding Y, Li D, Zhou J

Received 24 February 2014

Accepted for publication 8 April 2014

Published 3 July 2014 Volume 2014:7 Pages 1215—1221

DOI https://doi.org/10.2147/OTT.S62946

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5


Yuling Xi,1 Ming Chen,1 Xinmin Liu,1 Zhongmin Lu,1 Yi Ding,1 Datong Li2

1First Affiliated Hospital of Xinxiang Medical University, 2Hualan Vaccine, Xinxiang, People's Republic of China

Abstract: Lung cancer is the leading cause of cancer mortality in the world. Although some advances in lung cancer therapy have been made, patient survival is still poor. The platelet-derived growth factor receptors (PDGFRs) and their ligands play critical roles in the regulation of many cancer cell processes, including cell survival and cell motility. Herein, we investigate the anticancer activities of CP-673451, a potent selective inhibitor of PDGFR kinase, in non-small-cell lung cancer (NSCLC) therapy. We found that CP-673451 is effective at suppressing cell viability, inducing cell apoptosis, and inhibiting cell migration and invasion by suppressing the PDGFR downstream signaling pathway in NSCLC cells. Furthermore, CP-673451 is effective at suppressing NSCLC tumor growth in vivo. In summary, our studies suggest that CP-673451 might be a promising therapeutic compound for NSCLC.

Keywords: CP-673451, platelet-derived growth factor receptors (PDGFRs), lung cancer, proliferation, migration


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]